Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
304 people get LMNX articles and Market Currents by email alert.
Get email alerts on LMNX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
In-Line Quarter for LuminexZacks Investment Research • Wed, May 12, 2010 -
Luminex: Risk Continues to Weigh on Stock PriceZacks Investment Research • Fri, Apr 9, 2010
-
-
-
Giving Luminex the Benefit of the DoubtTraderMark • Fri, Dec 12, 2008
-
-
-
-
-
-
UBS And Hedge Funds Disagree On These 4 StocksKapitall • Thu, Dec 20, 2012 -
-
-
-
-
-
Cepheid: Awesome Company, But OverpricedDave Westenberg • Fri, Aug 10, 2012
-
-
Rally Should Proceed: 3 Laggards, 2 Leaders To Help You Catch UpAlan Brochstein • Sun, Feb 5, 2012
-
-
Survey: Life Sciences Could Be In For A Rough YearStephen Simpson • Tue, Oct 25, 2011
-
-
20 Healthcare Stocks With Positive Accounts Receivable TrendsKapitall • Tue, Sep 13, 2011
-
-
12 Healthcare Stocks Undervalued By EPS TrendsKapitall • Thu, Sep 8, 2011
-
Luminex Corporation Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
Luminex Corporation Q3 2009 Earnings Call TranscriptThu, Nov 5, 2009
-
Luminex Corporation Q1 2009 Earnings Call TranscriptFri, May 8, 2009
-
Luminex Corporation Q4 2008 Earnings Call TranscriptFri, Feb 6, 2009
-
Luminex Corporation Q3 2008 Earnings Call TranscriptMon, Nov 24, 2008
-
Luminex Corporation Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Luminex Corporation Q1 Earnings Call TranscriptThu, May 29, 2008
-
Luminex Corporation Q3 2007 Earnings Conference Call TranscriptFri, Oct 26, 2007
-
at MarketWatch.com (Jun 3, 2013)
-
PR Newswire (May 28, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (Apr 29, 2013)
-
PR Newswire (Apr 8, 2013)
-
PR Newswire (Feb 4, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 16, 2013)
-
PR Newswire (Jan 2, 2013)
-
PR Newswire (Nov 27, 2012)
-
PR Newswire (Oct 29, 2012)
-
PR Newswire (Oct 8, 2012)
-
PR Newswire (Oct 1, 2012)
-
PR Newswire (Sep 12, 2012)
-
PR Newswire (Sep 10, 2012)
-
PR Newswire (Aug 31, 2012)
-
PR Newswire (Aug 9, 2012)
LMNX vs. ETF Alternatives
Company Description
Currently, there's no company description for LMNX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, June 11, 12:41 PM Shares of GenMark Diagnostics (GNMK -25%) get slammed after one of its customers, Natural Molecular Testing, launches their laboratory developed comprehensive Personalized Medicine Panel using Luminex's (LMNX +6%) xMAP technology. Terms of the multi-year collaboration and license agreement were not disclosed. Comment! [Healthcare, On the Move]
- Monday, April 29, 4:37 PM Luminex (LMNX): Q1 EPS of $0.19 beats by $0.11. Revenue of $53.2M (+9% Y/Y) beats by $1.26M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, April 15, 8:50 AM Luminex (LMNX) receives FDA approval for its MAGPIX instrument with xTAG Gastrointestinal Pathogen Panel. The instrument can perform multiple GI tests in hours, a vast improvement from traditional methods which took several days to perform a single test, according to the company. Shares +1.5% premarket. Comment! [Healthcare]
- Tuesday, March 26, 12:31 PM Luminex (LMNX -4.5%) slips after Wedbush initiated coverage with a cautious Neutral rating and $17 price target - near current levels. Wedbush says the company's business with Labcorp is slipping, and increasing competitive risks in the key respiratory diagnostics business, along with potential headwinds following the heavy Q113 flu season, leave its current multiple in question. The firm adds that the stock is presently trading at a premium to the life science tools group, and near-term expectations are too high. Comment! [Healthcare, On the Move]
- Wednesday, March 13, 8:56 AM Luminex (LMNX) signs a deal to develop a diagnostic device that will help screen patients for recruitment into Merck's (MRK) clinical trials for MK-8931, its lead investigational candidate for Alzheimer's disease (AD). (PR) Comment! [Healthcare]
- Monday, February 4, 4:57 PM Luminex (LMNX): Q4 EPS of $0.12 beats by $0.04. Revenue of $55.5M (+16% Y/Y) beats by $1.41M. (PR) Comment! [Earnings, Breaking News, Tech]
- Tuesday, January 15, 10:14 AM Luminex (LMNX +2.7%) trades back down to earth following a +10% jump at the open after receiving FDA clearance for its xTAG Gastrointestinal Pathogen Panel, the first comprehensive molecular diagnostic assay that tests for greater than 90% of infectious causes of gastroenteritis in a single test. Comment! [Healthcare, On the Move]
- Monday, January 14, 11:03 AM Luminex (LMNX -5.9%) slips this morning after Cowen cut the shares to Underperform, commenting in a note to clients that "competitive pressures have intensified" for it's molecular-diagnostics franchise. This, combined with a lack of significant near-term catalysts and a still-rich valuation, means it's likely to lag its peer group over the next 12 months. Comment! [On the Move]
- Monday, October 29, 2012, 4:58 PM Luminex (LMNX): Q3 EPS of $0.04 misses by $0.02. Revenue of $50M (+10% Y/Y) misses by $1.2M. (PR) Comment! [Earnings, Tech]
- Thursday, August 23, 2012, 10:45 AM Luminex (LMNX +5%) pops on a UBS upgrade to Buy on valuation. UBS thinks the stock has been oversold recently on the back of its dilutive acquisition GenturaDx, plus negative press over its Biowatch sensors. The investment bank said in a note to clients it sees multiple expansion through launches, and that a high percentage of recurring revenues and a focus on clinical markets "makes for a favorable profile amidst macro challenges. Comment! [Healthcare, On the Move]
- Monday, July 30, 2012, 5:11 PM Luminex (LMNX): Q2 EPS of $0.07 misses by $0.01. Revenue of $48.3M (+1.5% Y/Y) misses by $1M. (PR) Comment! [Earnings, Tech]
- Monday, July 23, 2012, 1:55 PM Luminex (LMNX 0.9%) trades up today despite a bleak overall market on a Leerink upgrade to Outperform from Market Perform, citing the company's acquisition of GenturaDx and expectations for FDA clearance of its gastrointestinal pathogen panel. Comment! [Healthcare, On the Move]
- Monday, July 9, 2012, 12:28 PM Luminex (LMNX -15%) shares slide after the developer of biological testing technologies says it will acquire GenturaDx for $50M subject to working capital reconciliation and potential additional contingent consideration for achievement of future milestones and/or product revenue. LMNX anticipates the deal will add ~$6M in 2012 operating expenses. Comment! [Healthcare, M&A, On the Move]
- Monday, April 30, 2012, 5:05 PM Luminex (LMNX): Q1 EPS of $0.08 misses by $0.01. Revenue of $48.7M (+12.5% Y/Y) in-line. (PR) Comment! [Earnings]
- Tuesday, April 3, 2012, 12:22 PM Bio-Rad Labs (BIO +12.3%) shares surge after the company says it has extended its marketing deal with research tool maker Luminex (LMNX +0.2%). Under the deal, BIO will hold the worldwide sales and distribution rights to LMNX's Magpix multiplexing instrument. Comment! [Healthcare, On the Move]
- Monday, February 6, 2012, 5:29 PM Luminex (LMNX): Q4 EPS of $0.11 beats by $0.04. Revenue of $47.9M (+16.3% Y/Y) in-line. (PR) Comment! [Earnings, Tech]
-
- View all 0 replies
-
- View all 0 replies
-
Alan Brochstein
$LMNX is being taken to the woodshed - a very oversold high quality growth stock that should be bought after tax-loss selling ends - View all 0 replies
-
- View all 0 replies
-
Alan Brochstein
UBS upgrades $LMNX to buy but target is only 22??? Stock could get to 30 by year-end 2013 - View all 2 replies
-
-
Alan Brochstein: Sales Growth from tests - don't focus on PE, as company is quite young. Should trade 4-5X sales if they do what i think (20% sales growth)
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
Alan Brochstein: Turns out that it's not down on just the news - LA Times article this weekend through cold water on BioWatch
-
- View all 0 replies
LATEST REPLIES
-
Alan Brochstein
UBS upgrades $LMNX to buy but target is only 22??? Stock could get to 30 by year-end 2013 - View all 2 replies
-
-
Alan Brochstein: Sales Growth from tests - don't focus on PE, as company is quite young. Should trade 4-5X sales if they do what i think (20% sales growth)
-
- View all 1 replies
-
Alan Brochstein: Turns out that it's not down on just the news - LA Times article this weekend through cold water on BioWatch